Allakos Inc.

105.00-3.00-2.78%Vol 165.48K1Y Perf 68.45%
Apr 9th, 2021 16:00 DELAYED
BID104.90 ASK114.00
Open108.36 Previous Close108.00
Pre-Market- After-Market-
 - -  - -%
Target Price
180.80 
Analyst Rating
Moderate Buy 2.33
Potential %
72.19 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap5.58B 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
48.30 
Earnings Date
10th May 2021

Today's Price Range

104.93108.57

52W Range

55.51157.98

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-7.98%
1 Month
-12.62%
3 Months
-17.80%
6 Months
27.29%
1 Year
68.45%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ALLK105.00-3.0000-2.78
AAPL132.992.63002.02
GOOG2 285.8820.44000.90
MSFT255.852.60001.03
XOM55.87-0.1300-0.23
WFC40.500.47001.17
JNJ161.25-1.7200-1.06
FB312.46-0.5600-0.18
GE13.600.15001.12
JPM156.281.16000.75
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.85-0.86-1.18
Q03 2020-0.83-0.86-3.61
Q02 2020-0.63-0.80-26.98
Q01 2020-0.62-0.578.06
Q04 2019-0.50-0.51-2.00
Q03 2019-0.45-0.47-4.44
Q02 2019-0.49-0.4410.20
Q01 2019-0.35-0.47-34.29
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.7817.02Positive
6/2021 QR-0.927.07Positive
12/2021 FY-3.93-6.22Negative
12/2022 FY-5.632.43Positive
Next Report Date10th May 2021
Estimated EPS Next Report-0.78
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume165.48K
Shares Outstanding53.12M
Trades Count4.45K
Dollar Volume34.38M
Avg. Volume286.14K
Avg. Weekly Volume166.33K
Avg. Monthly Volume228.18K
Avg. Quarterly Volume264.78K

Allakos Inc. (NASDAQ: ALLK) stock closed at 105 per share at the end of the most recent trading day (a -2.78% change compared to the prior day closing price) with a volume of 165.48K shares and market capitalization of 5.58B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 114 people. Allakos Inc. CEO is Robert Alexander.

The one-year performance of Allakos Inc. stock is 68.45%, while year-to-date (YTD) performance is -25%. ALLK stock has a five-year performance of %. Its 52-week range is between 55.51 and 157.98, which gives ALLK stock a 52-week price range ratio of 48.30%

Allakos Inc. currently has a PE ratio of -36.90, a price-to-book (PB) ratio of 9.32, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -23.94%, a ROC of -28.32% and a ROE of -25.71%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Allakos Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.78 for the next earnings report. Allakos Inc.’s next earnings report date is 10th May 2021.

The consensus rating of Wall Street analysts for Allakos Inc. is Moderate Buy (2.33), with a target price of $180.8, which is +72.19% compared to the current price. The earnings rating for Allakos Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Allakos Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Allakos Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 13.60, ATR14 : 8.44, CCI20 : -45.76, Chaikin Money Flow : -0.20, MACD : -4.27, Money Flow Index : 43.94, ROC : -3.52, RSI : 43.29, STOCH (14,3) : 39.05, STOCH RSI : 0.81, UO : 37.26, Williams %R : -60.95), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Allakos Inc. in the last 12-months were: Adam Tomasi (Option Excercise at a value of $87 963), Adam Tomasi (Sold 63 189 shares of value $7 688 943 ), Daniel S. Janney (Sold 16 885 shares of value $2 102 053 ), Henrik S. Rasmussen (Option Excercise at a value of $127 875), Henrik S. Rasmussen (Sold 111 952 shares of value $12 905 844 ), John P. Mckearn (Sold 2 300 000 shares of value $163 392 000 ), Robert Alexander (Option Excercise at a value of $35 535)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (66.67 %)
2 (66.67 %)
2 (66.67 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (33.33 %)
1 (33.33 %)
1 (33.33 %)
Summary RatingModerate Buy
2.33
Moderate Buy
2.33
Moderate Buy
2.33

Allakos Inc.

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.

CEO: Robert Alexander

Telephone: +1 650 597-5002

Address: 975 Island Drive, Redwood City 94065, CA, US

Number of employees: 114

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

69%31%

Bearish Bullish

57%43%

Bearish Bullish

53%48%

News

Stocktwits